Melatonin versus placebo in the treatment of sleep disorders in children and adolescents with autism: Systematic review and meta-analysis
Abstract
Objective: To systematically review the evidence on the use of melatonin in the treatment of sleep disorders in children and adolescents with autism spectrum disorder (ASD). Method: Systematic review of randomized controlled clinical trials on the use of melatonin and included children and adolescents with ASD and sleep disorders, searching MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, in the period between September and October 2023. The selection of studies were carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Changes in Total Sleep Time (TST) and Sleep Latency (SL) measurements were statistically significant. The 95% CI of 1.66 [1.10, 2.23] and 2.55 [1.02, 4.08] showed an increase in TST with the use of the intervention. (p < 0.00001) [18, 19]. Garstang showed a statistical difference with the use of melatonin, with the result of 95% CI of -5.96 [-8.77, -3.16], as well as Cortesi with a 95% CI of -1.23 [-1.75, - 0.70] and Gringras with -1.35 [-1.79, -0.91], with reduced latency to start sleep (p = 0.0002). Conclusions: Larger samples are needed to evaluate the effectiveness of melatonin on other sleep patterns, such as nighttime awakenings and sleep quality.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.